These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 39080094

  • 1. Attentiveness and mental health in adolescents with moderate-to-severe atopic dermatitis without ADHD.
    Paller AS, Gonzalez ME, Barnum S, Jaeger J, Shao L, Ozturk ZE, Korotzer A.
    Arch Dermatol Res; 2024 Jul 30; 316(8):497. PubMed ID: 39080094
    [Abstract] [Full Text] [Related]

  • 2. Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2).
    Silverberg JI, Gooderham MJ, Paller AS, Deleuran M, Bunick CG, Gold LFS, Hijnen D, Calimlim BM, Lee WJ, Teixeira HD, Hu X, Zhang S, Yang Y, Grada A, Platt AM, Thaçi D.
    Am J Clin Dermatol; 2024 May 30; 25(3):485-496. PubMed ID: 38528257
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial.
    Simpson EL, Silverberg JI, Thyssen JP, Viguier M, Thaçi D, de Bruin-Weller M, Weidinger S, Chan G, DiBonaventura M, Biswas P, Feeney C, Koulias C, Cork MJ.
    Am J Clin Dermatol; 2023 Jul 30; 24(4):609-621. PubMed ID: 37213005
    [Abstract] [Full Text] [Related]

  • 4. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis.
    Yosipovitch G, Reaney M, Mastey V, Eckert L, Abbé A, Nelson L, Clark M, Williams N, Chen Z, Ardeleanu M, Akinlade B, Graham NMH, Pirozzi G, Staudinger H, Plaum S, Radin A, Gadkari A.
    Br J Dermatol; 2019 Oct 30; 181(4):761-769. PubMed ID: 30729499
    [Abstract] [Full Text] [Related]

  • 5. Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes.
    Silverberg JI, Thyssen JP, Simpson EL, Yosipovitch G, Ständer S, Valdez H, Rojo R, Biswas P, Myers DE, Feeney C, DiBonaventura M.
    Am J Clin Dermatol; 2021 Jul 30; 22(4):541-554. PubMed ID: 33954933
    [Abstract] [Full Text] [Related]

  • 6. Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.
    Ständer S, Kwatra SG, Silverberg JI, Simpson EL, Thyssen JP, Yosipovitch G, Zhang F, Cameron MC, Cella RR, Valdez H, DiBonaventura M, Feeney C.
    Am J Clin Dermatol; 2023 Jan 30; 24(1):97-107. PubMed ID: 36512175
    [Abstract] [Full Text] [Related]

  • 7. Symptoms and diagnosis of anxiety and depression in atopic dermatitis in U.S. adults.
    Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, Ong PY, Chiesa Fuxench ZC, Simpson EL.
    Br J Dermatol; 2019 Sep 30; 181(3):554-565. PubMed ID: 30838645
    [Abstract] [Full Text] [Related]

  • 8. Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1.
    Simpson EL, Blauvelt A, Silverberg JI, Cork MJ, Katoh N, Mark T, Schneider SKR, Wollenberg A.
    Am J Clin Dermatol; 2024 Jan 30; 25(1):139-148. PubMed ID: 37804473
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study.
    Paller AS, Flohr C, Eichenfield LF, Irvine AD, Weisman J, Soung J, Pinto Correia A, Natalie CR, Rodriguez Capriles C, Pierce E, Reifeis S, Gontijo Lima R, Armengol Tubau C, Laquer V, Weidinger S.
    Dermatol Ther (Heidelb); 2023 Jul 30; 13(7):1517-1534. PubMed ID: 37318750
    [Abstract] [Full Text] [Related]

  • 11. Assessing Response in Atopic Dermatitis: A Systematic Review of the Psychometric Performance of Measures Used in HTAs and Clinical Trials.
    Penton H, Jayade S, Selveindran S, Heisen M, Piketty C, Ulianov L, Jabbar-Lopez ZK, Silverberg JI, Puelles J.
    Dermatol Ther (Heidelb); 2023 Nov 30; 13(11):2549-2571. PubMed ID: 37747670
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2).
    Simpson EL, Prajapati VH, Leshem YA, Chovatiya R, de Bruin-Weller MS, Ständer S, Pink AE, Calimlim BM, Lee WJ, Teixeira H, Ladizinski B, Hu X, Yang Y, Liu Y, Liu M, Grada A, Platt AM, Silverberg JI.
    Dermatol Ther (Heidelb); 2024 May 30; 14(5):1127-1144. PubMed ID: 38696027
    [Abstract] [Full Text] [Related]

  • 14. Psychometric validation and responder definition of the sleep disturbance numerical rating scale in moderate-to-severe atopic dermatitis.
    Puelles J, Fofana F, Rodriguez D, Silverberg JI, Wollenberg A, Dias Barbosa C, Vernon M, Chavda R, Gabriel S, Piketty C.
    Br J Dermatol; 2022 Feb 30; 186(2):285-294. PubMed ID: 34608623
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis.
    Silverberg JI, DeLozier A, Sun L, Thyssen JP, Kim B, Yosipovitch G, Nunes FP, Gugiu PC, Doll HA, Eichenfield LF.
    Health Qual Life Outcomes; 2021 Oct 23; 19(1):247. PubMed ID: 34688290
    [Abstract] [Full Text] [Related]

  • 17. Association of Inadequately Controlled Disease and Disease Severity With Patient-Reported Disease Burden in Adults With Atopic Dermatitis.
    Simpson EL, Guttman-Yassky E, Margolis DJ, Feldman SR, Qureshi A, Hata T, Mastey V, Wei W, Eckert L, Chao J, Arnold RJG, Yu T, Vekeman F, Suárez-Fariñas M, Gadkari A.
    JAMA Dermatol; 2018 Aug 01; 154(8):903-912. PubMed ID: 29971354
    [Abstract] [Full Text] [Related]

  • 18. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
    Blauvelt A, Guttman-Yassky E, Paller AS, Simpson EL, Cork MJ, Weisman J, Browning J, Soong W, Sun X, Chen Z, Kosloski MP, Kamal MA, Delevry D, Chuang CC, O'Malley JT, Bansal A.
    Am J Clin Dermatol; 2022 May 01; 23(3):365-383. PubMed ID: 35567671
    [Abstract] [Full Text] [Related]

  • 19. Exploring the interplay of atopic dermatitis severity with sleep and mental health: a case-control study in adult patients.
    Esposito M, Amicucci G, Salfi F, Pellegrini C, De Berardinis A, Chiricozzi A, Peris K, Tempesta D, Ferrara M, Fargnoli MC.
    Postgrad Med; 2024 Jun 01; 136(5):533-540. PubMed ID: 38864389
    [Abstract] [Full Text] [Related]

  • 20. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder.
    Klassen AF, Miller A, Fine S.
    Pediatrics; 2004 Nov 01; 114(5):e541-7. PubMed ID: 15520087
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.